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I M M U N O L O G Y
A systematic approach to simultaneously evaluate 
safety, immunogenicity, and efficacy of novel 
tuberculosis vaccination strategies
Visai Muruganandah1,2, Harindra D. Sathkumara1, Saparna Pai1, Catherine M. Rush1,3, 
Roland Brosch4, Ashley J. Waardenberg1,5, Andreas Kupz1*
Tuberculosis (TB) is the deadliest infectious disease worldwide. Bacille-Calmette-Guérin (BCG), the only licensed 
TB vaccine, affords variable protection against TB but remains the gold standard. BCG improvement is focused 
around three strategies: recombinant BCG strains, heterologous routes of administration, and booster vaccination. 
It is currently unknown whether combining these strategies is beneficial. The preclinical evaluation for new TB 
vaccines is heavily skewed toward immunogenicity and efficacy; however, safety and efficacy are the dominant 
considerations in human use. To facilitate stage gating of TB vaccines, we developed a simple empirical model to 
systematically rank vaccination strategies by integrating multiple measurements of safety, immunogenicity, and 
efficacy. We assessed 24 vaccination regimens, composed of three BCG strains and eight combinations of delivery. 
The model presented here highlights that mucosal booster vaccination may cause adverse outcomes and provides 
a much needed strategy to evaluate and rank data obtained from TB vaccine studies using different routes, strains, 
or animal models.
INTRODUCTION
Tuberculosis (TB) kills more people annually than any other infec-
tious disease (1). Currently, live-attenuated Bacille-Calmette-Guérin 
(BCG) is the only licensed TB vaccine for human use. Although it 
has good ability to prevent extrapulmonary forms of TB in young 
children such as TB meningitis and miliary TB, the capacity of BCG 
to protect against pulmonary TB, the most common and transmis-
sible form of the disease, is variable (2). Nonetheless, BCG continues 
to be widely administered intradermally in many TB endemic coun-
tries. To reach the World Health Organization’s 2035 The End TB 
Strategy goal of reducing the incidence of TB by 90% (1), and to stop 
the rise of multidrug-resistant strains of Mycobacterium tuberculosis 
(Mtb), the causative agent of TB, more efficacious vaccines are needed. 
Over the past two decades, several new TB vaccine candidates have 
been developed and are currently undergoing clinical testing. In ad-
dition to subunit vaccines composed of selected dominant Mtb anti-
gens (3, 4), live recombinant BCG strains and attenuated Mtb strains 
appear to be among the most promising vaccine candidates (5). It 
has also recently become apparent that the route of vaccine admin-
istration and whether the vaccine requires a booster application 
critically influence stage-gating decisions during the clinical devel-
opment of novel TB vaccines. For example, a recently completed 
trial in South Africa that assessed the prevention of Mtb infection in 
neonatally BCG-vaccinated adolescents via booster immunization 
with the subunit vaccine candidate H4:IC31 or BCG, demonstrated 
a significant reduction in sustained QuantiFERON conversion by 
BCG revaccination (4). Although these results contrast with an earlier 
BCG revaccination trial in Brazil (6), they warrant further investiga-
tions into the importance of BCG booster application and whether 
this should occur by altering the route of administration or by engi-
neering BCG to express additional antigens. While animal models 
can contribute to systematically answer these questions, there remains 
a discrepancy between preclinical studies, where immunogenicity and 
efficacy parameters are often prioritized, and clinical practice, where 
safety and efficacy are the dominant considerations.
Mtb has evolved various mechanisms to modulate and evade host 
immune functions such as phagolysosome fusion and antigen pre-
sentation to survive and replicate within macrophages. The ESX 
(type VII) secretion systems, while nonessential for bacterial growth, 
appear to be necessary for conferring virulence (7). Encoded within 
the region of difference 1 (RD1), early secreted antigenic target 
(ESAT)-6 secretion system-1 (ESX-1) is thought to play a role in 
phagosome disruption and activation of cytosolic pathogen recogni-
tion receptors. Genomic deletion of RD1 results in attenuation of Mtb, 
further implicating ESX-1 in virulence (8, 9). All Mycobacterium bovis 
BCG strains, including those currently licensed for human use, lack 
RD1. Although an experimental strain of BCG reconstituted with an 
extended RD1 region from Mtb (BCG::RD1) has been demonstrated 
to reduce Mtb replication, it maintains proliferative capacity in lung 
and splenic tissues of immunocompromised mice, rendering this 
strain too virulent for human vaccine use (10). However, we have 
recently shown that ESX-1–mediated cytosolic contact of ESAT-6 is 
required to activate protective immune responses against TB (11). 
In this study, rapid secretion of interferon- (IFN-) only occurred 
when full-length ESAT-6 was secreted via ESX-1 but not when a 
C-terminal truncated version of ESAT-6, unable to reach the host 
cell cytosol, was expressed (BCG::RD1 ESAT-6 92–95). Furthermore, 
improved protection against TB conferred by intravenous vaccination 
with BCG::RD1 at day 45 was lost when mice were vaccinated with 
BCG::RD1 ESAT-6 92–95 (11). These findings support increasing 
evidence that initiation of cytosolic contact, as conferred by many 
recombinant BCG strains, improves protection (12).
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In murine models, protection against TB generated through par-
enteral BCG administration relies on the induction of T helper 1 
(TH1) CD4+ memory lymphocytes (13, 14). However, many of the 
vaccine-induced lymphocytes lack the necessary mucosal-homing 
chemokine receptors to migrate into pulmonary tissue. This results 
in a delay in activation and recruitment of TB-specific effector (TEM) 
and central (TCM) memory lymphocytes to the lungs, allowing Mtb to 
infiltrate macrophages, proliferate, and establish chronic infection. In 
addition, a third type of memory T lymphocyte, largely CD69+CD103+ 
cells, called tissue-resident memory T lymphocytes (TRM), have recently 
been found to take permanent residence in nonlymphoid tissues. 
These cells are ideally situated in portals of entry, allowing them to 
mount timely recall responses unlike their circulating counterparts 
(15, 16) and hence present as a possible cellular target for vaccination 
strategies.
Several studies have demonstrated that mucosal administration 
of BCG results in the generation of significant numbers of protective 
anti-TB airway TRM (17–19). This suggests that the current protocol 
of administering vaccines parenterally needs to be reconsidered, with 
mucosal vaccination strategies appearing more efficacious (20). This 
also agrees with findings by Calmette and Guérin (21), published in 
1931, that BCG vaccination administered via the oral route demon-
strates good results. It has also been shown that TRM can be generated 
in a number of peripheral barrier tissues (skin and mucosa) using the 
“prime and pull” booster vaccination method (22). In this strategy, 
memory lymphocytes are systemically primed using a traditional sub-
cutaneous vaccination, followed by topical administration of inflam-
matory agents such as chemokines to the desired peripheral tissue. 
However, this strategy appears to be dependent on local antigen 
presence for generation of TRM within the lung. Thus, a live vaccine 
capable of initially replicating in the host and maintaining antigenic 
stimulation may be more effective.
Despite these many efforts to develop more efficacious TB vac-
cines, intradermal BCG vaccination remains the gold standard. To 
facilitate preclinical decision-making and stage gating, here we used a 
systematic and comprehensive approach to investigate if a combina-
tion of recombinant BCG (rBCG) strains that express Mtb-specific 
antigens (BCG::RD1 and BCG::RD1 ESAT-6 92–95), heterologous 
route vaccination [intratracheal (IT) and/or subcutaneous (SC)], and 
booster vaccination strategies can enhance protection against aerosol 
Mtb challenge and induce TRM. While C57BL/6 mice are the most 
commonly used preclinical small-animal model to study immuno-
genicity and efficacy in preclinical BCG development (representative 
of largely resistant healthy humans), SCID (severe combined immuno-
deficient) mice are traditionally used to assess the safety of live vac-
cines. To allow comprehensive safety evaluation within the C57BL/6 
model itself, we have analyzed clinical, histological, and chemical 
pathology, such that safety can be evaluated simultaneously with 
immunogenicity studies. All parameters were compared to the 
current BCG protocol (represented by BCG::pYUB, a BCG strain 
containing a gene empty vector). An “empty vector” BCG control 
has been used to account for any effects that the vector may have on 
microbial fitness in vivo. In doing so, we developed an empirical 
model to integrate multiple measurements of safety, immunogenicity, 
and efficacy to rank each vaccination strategy. Using this approach, 
we find that (i) the expression of immunodominant antigens from 
the Mtb genome is the most effective way to enhance efficacy of BCG, 
(ii) that the mucosal administration of BCG booster doses is cor-
related with adverse safety outcomes, and (iii) that immunogenicity 
readouts do not predict efficacy. The model presented here provides 
a much needed strategy for the TB vaccine community to evaluate 
and rank data obtained from vaccine studies using different routes, 
strains, or animal models.
RESULTS
The experimental outline and experimental groups are shown in Fig. 1.
Vaccine safety
Throughout the vaccine period, animal weight and signs of disease 
were monitored as clinical indicators of health. Sixty days after prime 
vaccination, vaccine clearance, lung histology, and serum cytokine 
profiles were analyzed. These parameters were selected as indicators 
of either lung or systemic health.
In vivo persistence of BCG is dependent on the route of  
vaccination and strain characteristics
The persistence of viable mycobacteria in the lung and splenic 
tissue of animals following vaccination was investigated as an indi-
cator of local and systemic clearance of the vaccines. Sixty days 
following prime vaccination, viable bacilli were readily recovered 
from lung tissue of animals that were IT vaccinated, while minimal 
colony- forming units (CFU) were recovered from lung tissue of 
animals that received only SC vaccination(s) (Fig. 2A). Furthermore, 
IT vaccination resulted in higher CFU numbers in the splenic tissue 
when compared with SC vaccinated animals (Fig. 2B), indicating 
that IT delivery may allow for widespread dissemination of bacilli. 
Only BCG::pYUB and BCG::RD1 persisted in the lung tissue in 
significant amounts in some groups that received an IT vaccination. 
The number of bacilli recovered from the lung tissue of BCG::RD1 
ESAT-6 92–95–vaccinated mice was not significant, suggesting 
that this strain may be the most readily cleared from the lungs. 
The number of bacilli in lung tissues tends to reduce with time in 
all IT-vaccinated groups (Fig. 2A; -IT versus IT-). On the contrary, 
viable BCG::RD1 ESAT-6 92–95 and BCG::RD1 remained in splenic 
tissue in significant amounts in more groups than BCG::pYUB.
IT vaccination induces inflammatory changes in the lung
To further assess the safety of each vaccination strategy, we assessed 
histological changes in lung tissue 60 days after the initial prime 
vaccination. In line with previous studies (17), hematoxylin and eosin 
(H&E) staining of lung sections from immunized animals revealed 
that IT BCG vaccination induced inflammatory changes in the lung 
parenchyma (Fig. 2C), including the presence of foamy macrophages, 
lymphocyte, and granulocyte infiltration. While some areas of 
tissue infiltration in close proximity to bronchioles resembled highly 
organized structures evocative of inducible bronchus-associated 
lymphoid tissue (iBALT) (Fig. 2C, green arrow head), other changes 
included edema and generalized foci of inflammation (Fig. 2C, yellow 
arrow head). Areas of consolidation and/or increased leukocyte infil-
tration were considered altered regardless of the pattern of inflam-
mation (Fig. 2C, green and yellow arrow heads). Inflammation was 
almost completely absent in lung sections of animals that received 
only SC vaccination(s) and resembled the lung architecture of 
unvaccinated (naïve) animals (Fig. 2C, red arrowhead). IT vaccina-
tion, however, induced widespread inflammatory changes of hetero-
geneous patterns. Morphometric quantitation was performed, where 
the percentage of area affected by these changes was calculated 
(Fig. 2E). Animals vaccinated with BCG::pYUB and BCG::RD1 
exhibited the greatest amounts of inflammation, while changes 
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observed in animals vaccinated with BCG::RD1 ESAT-6 92–95 did 
not reach significance (Fig. 2, D and E). Unexpectedly, all BCG::pYUB- 
immunized groups that received at least one IT vaccination demon-
strated significant amounts of inflammation. BCG::pYUB also induced 
the greatest amount of inflammation across all vaccine strategies 
that involved IT vaccination. Comparison of groups that received a 
single IT vaccination at different time points suggested that these 
inflammatory changes were transient, as the percentage of lung 
involvement tended to reduce with time in BCG::pYUB- and 
BCG::RD1-vaccinated groups. Although this was not true for 
BCG::RD1 ESAT-6 92–95–vaccinated mice, the changes induced 
in these animals were not significant at either time point, and thus, 
the slight increase in inflammatory change observed following 
BCG::RD1 ESAT-6 92–95 vaccination may be negligible. It is, 
however, important to note that due to the large number of com-
parisons and multiple hypothesis testing in this study, individual 
comparisons among the entire group did not always pass our signifi-
cance threshold, despite individual comparisons to unvaccinated 
mice across fewer groups showing statistical significance. Further 
investigation is needed regarding the different types of inflammation 
observed and whether pathological changes affect respiratory function 
or are protective structures that mediate immunity.
IT administration of booster vaccinations causes a transient 
state of illness
A single SC or IT vaccination did not cause any noticeable signs of 
disease, regardless of the vaccine strain administered. Body weights 
of these animals mirrored those of unvaccinated controls. However, 
animals that received a prime-boost vaccination strategy, where the 
booster was administered via the IT route (SCIT and ITIT; see table in 
Fig. 1), exhibited signs of illness following the booster dose. These 
animals suffered loss of weight and displayed clinical signs of illness 
including dyspnea, lethargy, and anorexia, 24 to 48 hours following 
the IT booster, with some animals euthanized for ethical reasons 
(three mice in the BCG::pYUB SCIT group and two mice in the 
BCG::RD1 SCIT group). The SCIT vaccination strategy had the 
greatest effect on health (Fig. 2F). Although this phenomenon was 
consistent among all vaccine strains investigated, animals vacci-
nated with BCG::pYUB developed the most severe clinical signs 
and suffered the greatest weight loss, while BCG::RD1-vaccinated 
animals were the slowest to regain weight. Despite this transient 
state of illness, animals appeared to recover as indicated by weight 
gain and returned to normal health scores by day 60. Collectively, 
these results imply that an IT booster vaccination with a live whole- 
organism vaccine administered 20 days after prime vaccination may 
be unsafe.
Prime-boost vaccinations with BCG::RD1 induce a prolonged 
systemic inflammatory profile
To determine whether any of the vaccination strategies caused and 
maintained elevated levels of systemic cytokines, serum samples 
from vaccinated animals were analyzed for various chemokines 
and cytokines 60 days following prime vaccination (Fig. 3A). Across all 
vaccination strategies, a similar pattern was found. While proin-
flammatory cytokines are expected to increase immediately following 
vaccination, inflammation should subdue with time. Interleukin-1 
(IL-1), IL-6, and tumor necrosis factor– (TNF-) were used as 
markers of systemic inflammation due to their involvement in 
pathological hyperinflammatory states such as cytokine storm. None 
of the BCG::pYUB and BCG::RD1 ESAT-6 92–95–vaccinated groups 
exhibited an increase in systemic levels of IL-1, IL-6, and TNF- 
relative to unvaccinated controls at day 60. However, animals im-
munized with BCG::RD1 via SCSC and SCIT strategies had signifi-
cantly elevated levels of IL-1 and IL-6, respectively (Fig. 3B).
Fig. 1. Schematic representation of vaccination/infection model. Six- to 8-week-old female naïve C57BL/6 mice were vaccinated via the SC or IT route or left unvaccinated. 
Twenty days later, animals received a booster vaccination via the same or alternate route or did not receive a booster. During the vaccination period, mice were weighed 
weekly and assigned daily a clinical health score. Sixty days after prime vaccination, some mice from each group were euthanized, and clearance of bacilli from the lungs 
and spleen, cellular immune responses in the lung interstitium and airways, lung histology, and serum cytokine/chemokine profiles were studied (vaccine safety and 
immunogenicity). At day 90 after prime vaccination, remaining mice were aerosol infected with Mtb H37Rv. At day 118, Mtb colony-forming units (CFU) from lung tissue 
was enumerated, and lung histopathology was analyzed (vaccine efficacy). Three recombinant strains of BCG were investigated: BCG::pYUB (standard BCG reconstituted 
with an empty control plasmid conferring resistance to hygromycin, serving as the control strain), BCG::RD1, and BCG::RD1 ESAT-6 92–95. Together with unvaccinated 
mice, this resulted in a total of 25 experimental groups.
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Fig. 2. Vaccine safety. BCG CFU recovered from (A) lung tissue and (B) splenic tissue. (C) Representative images of iBALT-like structures (green arrowhead), generalized 
inflammation (yellow arrowhead), and normal lung tissue (red arrowhead) at ×40 magnification. (D) Representative H&E staining of lung sections from each experimental 
group at ×40 magnification. (E) Morphometric quantitation of histological changes presented as a percentage of the total lung area. (F) Weekly weight changes and 
health scores. Weight changes (top row) are presented as mean values from two pooled independent experiments (n = 6 to 13 mice per group). Health score results 
(bottom row) are presented as mean values from one representative experiment (n = 7 mice per group). (A to C) Presented as means ± SEM from two pooled independent 
experiments (n = 10 mice per group). The statistical significance of differences between each experimental group relative to unvaccinated controls is shown. *P < 0.05, 
**P < 0.01, ***P < 0.001, and ****P < 0.0001. The P values were determined using a one-way ANOVA followed by a Dunnett’s multiple comparison test.
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Vaccine immunogenicity
To assess the immunogenicity of each vaccination strategy, serum 
cytokine/chemokine profiles, serum immunoglobulin levels, and 
airway and lung interstitial immune cell composition were analyzed 
60 days after prime vaccination.
Parenteral vaccination is more likely to induce a TH1 cytokine 
milieu in the serum
TH1 effector responses have been implicated in the effective control of 
Mtb infection. Hence, key TH1 cytokine (IFN-, IL-2, and IL-12p70) 
levels in serum 60 days following prime vaccination were analyzed 
to determine which strategies established a TH1 profile. The only 
vaccination strategies that maintained significantly elevated levels of 
IFN-, IL-2, and/or IL-12p70 were BCG::RD1 -SC, BCG::RD1 SCSC 
as well as BCG::pYUB -SC and SCIT, respectively. None of the 
BCG::RD1 ESAT-6 92–95–vaccinated groups maintained any of 
these cytokines at significant amounts (Fig. 3C).
IT vaccination increased serum immunoglobulin A levels
Immunoglobulin A (IgA) has been associated with enhanced pro-
tection against Mtb (23). To determine which strategy induced the 
greatest humoral response, total serum IgA concentrations were 
measured 60 days after prime vaccinations. Although vaccination 




































































































































































































Fig. 3. Systemic cytokine/chemokine profile and serum IgA levels before Mtb infection. (A) Serum cytokines/chemokines 60 days following prime vaccination pre-
sented in a heat map. (B) Serum levels of IL-1, IL-6, and TNF- used as measures of systemic inflammation for vaccine safety studies. (C) Serum levels of key TH1 cytokines 
(IFN-, IL-2, and IL-12p70). (B and C) Presented as means ± SEM from two pooled independent experiments (n = 10 mice per group). (D) Serum levels of IgA used as a 
measure of humoral immunity for immunogenicity studies (n = 3 mice per group). The statistical significance of differences between each experimental group relative to 
unvaccinated controls is shown. *P < 0.05 and **P < 0.01. The P values were determined using a one-way ANOVA followed by a Dunnett’s multiple comparison test.
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strategies induced statistically significant increases in IgA levels 
(Fig. 3D). Nonetheless, strategies that included at least one IT vac-
cination appeared to induce a trend toward stronger IgA response 
when compared with SC vaccination alone.
IT vaccination with BCG::RD1 induces significantly increased 
number of airway TRM
Since airway TRM appears to be vital in protecting against Mtb (18) 
and interstitial TRM is thought to replenish airway TRM populations 
(24), phenotypic analysis of lymphocytes found in both compartments 
was performed. Sixty days following prime vaccination, bronchoal-
veolar lavage fluid (BALF) was harvested, and lungs were perfused 
with phosphate-buffered saline (PBS) through the right ventricle of 
the heart to eliminate lymphocytes that were not associated with 
pulmonary vasculature. Cells were isolated for flow cytometry to 
define and quantify the population of memory T lymphocytes gen-
erated in response to vaccination. IT vaccination generated in-
creased numbers of both CD4+ and CD8+ T lymphocytes within the 
airways and interstitium when compared with vaccination strategies 
that only included SC administration(s). Many of these lymphocytes 
displayed a memory phenotype (CD44hi). Most of the memory T cells 
were peripheral tissue–homing lymphocytes (CD44hiCD62Llo), al-
though substantial populations of central memory T lymphocytes 
(CD44hiCD62Lhi) were also observed (Fig. 4A and fig. S1A). The char-
acteristic coexpression of CD69 and CD103 within the CD44hiCD62Llo 
population was used to differentiate between TEM and TRM (Fig. 4B 
and fig. S1B). When all 24 groups were statistically compared with 
unvaccinated mice, only strategies that included the IT administra-
tion of BCG::RD1 induced a significant population of airway TRM 
(Fig. 4B). However, both BCG::pYUB and BCG::RD1 stimulated a 
significant TRM response in the lung interstitium (fig. S1, A and B), 
while BCG::RD1 ESAT-6 92–95 failed to do so in either compart-
ment. Combined heterologous route vaccination strategies appeared 
to reduce the generation of interstitial TRM, as the TRM population 
in the SCIT and ITSC groups did not reach significance.
Analysis of TRM based on the expression of CD4 and CD8 re-
vealed that CD8+ cells generally accounted for the largest proportion 
of TRM established in airways following vaccination (Fig. 4C). A dif-
ferent pattern was observed in the interstitium, where BCG::pYUB- 
immunized mice developed a larger population of CD4+ TRM, while 
BCG::RD1-immunized animals developed a higher proportion of CD8+ 
TRM (fig. S1C). Furthermore, double-negative T cells (CD4−CD8−) 
appeared to account for a smaller proportion of the TRM population 
in interstitium compared with airways. Lymphocytes were also stained 
for the CD4 major histocompatibility complex (MHC) peptide te-
tramer derived from the immunodominant Mtb antigen ESAT-6 
(QQWNFAGIEAAASA). Only groups vaccinated with a single dose 
of BCG::RD1 via the IT route established a significant population of 
tetramer+ cells in both the airways and lungs (Fig. 4D and fig. S1D). 
ITIT vaccination with BCG::RD1 appeared to markedly reduce te-
tramer+ cells in both compartments. In line with previously pub-
lished data regarding lung TRM retention (25), comparison of single 
IT vaccinations with BCG::RD1 at different time points (40 days, 
-IT; 60 days, IT-) also suggested that the population of tetramer+ TRM 
induced by IT vaccination may not persist in the long term. From 
our data, it appears that a single IT vaccination generated the most 
dynamic and robust T lymphocyte response in the airways and lung 
interstitium at day 60. Vaccination with BCG::RD1 ESAT-6 92–95 
did not induce tetramer+ cells. It has been demonstrated that secretion 
of mycobacterial antigens is essential for their efficient presentation 
to CD4+ T cells (26, 27). However, the situation in which biologically 
nonfunctional ESAT-6 molecules are secreted such as ESAT-6 92–95 
or the previously used ESAT-6 84–95 constructs opens new inter-
esting questions (28). Given that MHC-II peptide loading is not meant 
to involve cytosolic contact and that the C-terminal truncation of 
ESAT-6 does not overlap with the CD4+ T cell epitope tested, these 
results warrant further investigation into the role of ESAT-6–mediated 
cytosolic translocation for generation of ESAT-6–specific T cells.
Vaccine efficacy
To determine the effect of each vaccination strategy on Mtb clear-
ance and lung pathology, Mtb challenge experiments were conducted 
90 days after prime vaccination.
All vaccination strategies and strains conferred similar levels 
of protection against Mtb burden 28 days after infection
It has previously been reported that IT vaccination with BCG sig-
nificantly reduces the bacterial burden at 45 days following Mtb 
challenge (at which point bacterial burden plateaus) when compared 
to SC vaccination (17). We investigated whether ESAT-6–expressing 
rBCG and/or heterologous route prime-boost vaccination strategies 
would induce increased protection early after Mtb infection. Ninety 
days after the priming vaccination, mice were aerogenically chal-
lenged with an ultralow to low dose of Mtb H37Rv (5 to 80 CFU) 
and were euthanized 28 days later. All vaccination strategies demon-
strated significant reductions in Mtb CFU (1 to 1.5 log) when compared 
with unvaccinated controls (Fig. 5A). However, when compared 
holistically, there were no significant differences between experi-
mental groups, suggesting that neither the rBCG strains tested nor 
the heterologous route prime-boost vaccination strategies led to in-
creased protection at an earlier time point.
Vaccination with rBCG strains reduces lung pathology across 
vaccination strategies
Twenty-eight days following Mtb infection, histopathology analysis 
of H&E-stained lung sections and morphometric quantitation were 
performed (as described in the “Vaccine safety” section above). While 
some organized immune tissue changes reminiscent of tertiary lym-
phoid structures induced by IT vaccination were maintained, patho-
logical changes such as pneumonia, granulomatous-like inflammation, 
and diffuse alveolar damage were prominent (Fig. 2E). Whether lung 
pathology in IT BCG–vaccinated groups are attributable to changes 
induced by the IT vaccination itself (Fig. 5, B and C) requires further 
investigation. Across all groups, animals that received BCG::RD1 or 
BCG::RD1 ESAT-6 92–95 tended to suffer the least amount of 
lung pathology.
Vaccine empirical integrated model
To simultaneously evaluate experimental parameters of vaccine safety, 
immunogenicity, efficacy, and overall performance, we developed an 
integrated approach, the vaccine empirical integrated model (VEIM) 
(Fig. 6 and VEIM methods; Eqs. 1 to 3). VEIM considers (i) efficacy 
as the combined effect of reduced Mtb CFU and lung pathology after 
challenge; (ii) immunogenicity as the combined effect of TRM in 
BALF and lung, equally weighted levels of IL-2, IL-12p70, and IFN-, 
as well as IgA after vaccination; and (iii) safety as the combined ef-
fect of clinical score, weight reduction, lung and spleen bacterial 
burden, histopathological changes to the lung, and equally weighted 
levels of IL-1, IL-6, and TNF- after vaccination. For comparison, 
BCG::pYUB SC- was considered a representation of the current BCG 
strategy used clinically. Parenteral (SC- and SCSC) administration 
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Fig. 4. Airway immune cell profiles following vaccination. Sixty days following prime vaccination, animals were euthanized, and BALF was harvested for FACS analysis. 
(A) Representative FACS plots and enumeration of CD44hi T lymphocyte subsets TCM, TEM, and TRM. Indicated significance is of total memory T lymphocyte numbers. 
(B) Representative FACS plots and quantification of CD4+CD8− and CD8+CD4− and CD4−CD8− (DN) TRM. Indicated significance is of total TRM numbers. (C) Total numbers 
of CD4+, CD8+, and DN TRM. (D) Representative FACS plots showing the gating strategy to enumerate tetramer+ cells and total numbers of tetramer+ TRM. (E) Proportion 
of tetramer+ and tetramer− CD4+ TRM are also shown. (A to D) Results are presented as means ± SEM from two pooled independent experiments (n = 5 to 10 mice per 
group). The statistical significance of differences between each experimental group relative to unvaccinated controls is shown. *P < 0.05, **P < 0.01, ***P < 0.001, and 
****P < 0.0001. The P values were determined using a one-way ANOVA followed by a Dunnett’s multiple comparison test.
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of the more virulent BCG::RD1 ESAT-6 92–95 outperformed 
BCG::pYUB on safety, while BCG::RD1 SC- (previously deemed 
too unsafe for use in humans) ranked sixth (Fig. 6A). BCG::pYUB 
SC- appears to be one of the least efficacious vaccine strategies 
(Fig. 6C), while a single dose of BCG::RD1 obtained the greatest 
score for protection. Notably, vaccine strategies that ranked in 
the top half for efficacy were all rBCGs, while all BCG::pYUB- 
vaccinated groups ranked in the bottom half. This supports a model 
where the expression of key Mtb virulence factors is the most effec-
tive way of enhancing vaccine efficacy out of the strategies investi-
gated. Furthermore, some of the most efficacious strategies ranked 
at the bottom for immunogenicity (Fig. 6B). Using our model, it 
appears that the most efficacious and safe vaccine strategies are 
single or double SC doses of BCG::RD1 or BCG::RD1 ESAT-6 92–95 
(Fig. 6D and table S2). When efficacy, safety, and immunogenicity 
were combined into a single rank (fig. S3A), our integrated data 
analysis indicates that two doses of BCG::RD1 given SC appear to 
be the most favorable strategy overall (Fig. 6D). To account for the 
fact that vaccine safety is always paramount and is more important 
than efficacy and immunogenicity, we also performed three alter-
nate VEIM analyses, in which safety, immunogenicity, and efficacy 
were weighted differently to calculate the overall rankings (fig. 
S3B). In addition to equal ranking, the following situations were 
modeled: (i) safety as twice as important as efficacy and immunoge-
nicity, (ii) both safety and efficacy as twice as important as immuno-
genicity, and (iii) efficacy in-between safety (as most important) and 
immunogenicity (as least important). In all scenarios BCG::RD1 
SCSC remained the most favorable vaccination strategy, followed by 
single or double IT vaccinations with BCG::RD1. These findings sug-
gest that BCG strains expressing Mtb antigens should be reevaluated 
in the context of mucosal and/or booster application and demon-
strate that VEIM can be used in a versatile manner. VEIM also illus-
trates a disconnection between immunogenicity and protection of 
BCG strains more broadly (Fig. 6D), highlighting deficiencies in 
the understanding of true correlates of vaccine-induced protection 
against TB.
DISCUSSION
It is widely accepted that studies evaluating novel TB vaccine strat-
egies should include data regarding safety, immunogenicity, and 
efficacy. However, preclinical evaluation of new TB vaccines is 
biased toward immunogenicity and/or efficacy, and there remains 
no standard approach to integrating each of these parameters to 
determine how novel vaccine strategies perform overall in com-
parison to standard BCG. To address this, we used a systematic 
approach to evaluate and compare 24 vaccination regimens in the 
commonly used preclinical C57BL/6 mouse model. Upon completion 
of routinely performed data collection, we developed a model, VEIM, 
to rank vaccine strategies based on overall performance and simul-
taneous comparison of protection, immunogenicity, and safety. 
Our results show that expression of Mtb-specific immunodominant 
antigens is the most effective way to enhance efficacy of BCG and 

































































































































Fig. 5. Vaccine-induced protection and pulmonary pathology following Mtb infection. (A) Twenty-eight days following Mtb infection, animals were sacrificed, and 
the lungs were assessed for numbers of viable Mtb. (B) H&E-stained lung sections were analyzed for histopathology. (C) Representative H&E staining of lung sections from 
each group at ×40 magnification. (A and B) Presented as means ± SEM from two pooled independent experiments. (A) n = 7 to 12 mice per group and (B) n = 6 to 8 mice 
per group. The statistical significance of differences between each experimental group relative to unvaccinated controls is shown. Scale bar, 600 m. *P < 0.05, **P < 0.01, 
***P < 0.001, and ****P < 0.0001. The P values were determined using a one-way ANOVA followed by a Dunnett’s multiple comparison test.
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outcomes. VEIM also provides a tool to evaluate and rank data 
obtained from different TB vaccine studies.
SC administration of BCG provides some, but variable, protection 
against Mtb infection in murine models (14). Although TH1 immune 
responses have been implicated for protection, the exact immune 
response(s) that are responsible for reducing bacterial replication 
remain unknown (29). Following Mtb infection, TRM, a subset of 
memory T lymphocytes that take residence in peripheral tissue com-
partments has been observed in the lung tissue (30). It has also been 
shown that IT delivery of BCG enhances protection, correlating with 
increased TRM numbers (17). Our study tested the hypothesis that 
heterologous route prime-boost vaccination strategies would enhance 
vaccine efficacy and TRM numbers.
As previously demonstrated, CD4+ and CD8+ T lymphocyte num-
bers in the airways and lungs increased following IT vaccination, an 
increase not observed following standard parenteral vaccination. The 
statistically significant rise in TRM numbers following IT adminis-
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Fig. 6. Vaccine empirical integrated model. Simultaneous comparison of safety, immunogenicity, and efficacy through integration of measurements into single mea-
sures of their summed effects (Eqs. 1 to 3 and Materials and Methods). (A to C) Vaccine strategies ordered from right to left based on increased safety, immunogenicity, 
or efficacy. (D) Vaccines plotted on overall performance of immunogenicity versus efficacy. The size of circles (D) is scaled to safety effect, where the safest strategy is 
represented by the largest circle. The overall ranking of each vaccine strategy is indicated by the number next to the circle and as a bar graph.
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within a 20-day period (40 days after vaccination compared with 
60 days after vaccination). A similar decline in lung TRM has been 
previously reported in other infection models, suggesting that low 
retention of immunocytes is an intrinsic feature of lung tissue 
(25, 31). On the contrary, CD4+ TRM was found 12 months after 
SC BCG vaccination with no measurable reduction in cell numbers 
in a murine model (32). However, it must be acknowledged that 
Bull et al. used intravascular staining and focused on lymphocytes found 
in the parenchyma rather than interstitium. In the present study, we 
did not use intravascular staining as it was logistically not feasible 
given the large numbers of experimental groups involved in our 
study. IT vaccination with BCG::pYUB only significantly increased 
TRM numbers in lung tissue but not in the airway. Whether TRM 
frequency in the airway or the lung tissue is more relevant to ulti-
mate protective efficacy is currently unknown and requires further 
investigation. This also raises the question whether TRM induction 
is influenced by characteristics of the vaccine strain. In addition to 
the genetic modification of BCG, there has been renewed interest in 
BCG vaccinations administered through other routes such as intra-
venous, oral, and skin scarification (33). Whether inclusion of these 
routes of administration in prime-boost strategies can provide better 
protection while remaining safe is worth exploring.
It was beyond the scope of this study to determine which strategy 
mediated best protection at later time points. However, it is widely 
acknowledged that mucosal vaccination provides better protection 
against pulmonary TB in multiple animal models. In murine models, 
this differential protection is particularly evident at 45 days after 
infection and up until at least 100 days after infection (17). Since 
mucosal booster strategies were unable to provide this enhanced 
protection at an earlier time point and caused adverse health out-
comes, it may not be worth investigating the long-term protection 
mediated by these strategies, unless there are avenues to improve 
the safety of these strategies. The exact mechanisms of why animals 
vaccinated through SCIT and ITIT routes suffered weight loss and 
clinical illness are not clear, especially since these observations did 
not correlate with other parameters included in our study (although 
these additional parameters were only investigated after illness had 
subsided). While a single mucosal vaccination did not cause any 
adverse outcomes in our study, mucosal administration of BCG in 
macaques resulted in a slight (<3%) reduction in body weight 3 to 
4 weeks after vaccination (34). Repeated exposure of Mtb was found 
to cause greater lung pathology than a single exposure to the same 
CFU dose in a rabbit model (35). Perhaps the prime-boost strategies 
used in our study mimic repeated exposure to mycobacteria, inducing 
pulmonary damage, weight loss, and overall health deterioration. 
Dosing regimens used in the present study were guided by previous 
studies. Prime and booster vaccinations were spaced 20 days apart, 
as the BCG-induced systemic T lymphocyte response takes 2 to 
3 weeks to reach a substantial threshold. However, it is possible that 
the doses used were too high or too tightly administered in time. 
While IT vaccination is not applicable to a clinical setting, it was 
used in this study under a controlled experimental setting to elicit 
the mucosal immune response that is likely to occur in an aerosol 
delivery. Aerosol delivery was not used in this study as the number 
of bacilli delivered is highly variable, a separate problem for trans-
latability of live aerosol vaccines. Although modifying dose and/or 
prime and booster timing may result in safer vaccination strategies, in 
clinical settings and human challenge models, it will be almost im-
possible to determine when natural exposure may have last occurred.
Aside from assessing prime-boost BCG vaccination strategies, we 
also investigated ESAT-6’s role in generating mycobacteria-specific 
TRM and immunity. ESAT-6 is known to be a major T lymphocyte 
immunogen during Mtb infection, and lymphocyte restimulation 
with ESAT-6 is used as a diagnostic test for TB. In this study, we 
made use of an rBCG strain (BCG::RD1 ESAT-6 92–95) designed 
to express ESX-1– specific virulence factors, including a C-terminal 
truncated ESAT-6. Specific mutations of ESAT-6 have been demon-
strated to attenuate virulent mycobacterial species, potentially making 
them more suitable for use as vaccine strains (36). A previous study 
with BCG::RD1 ESAT-6 92–95, however, has demonstrated that it 
is less capable of protecting against Mtb infection than strains that 
express unaltered ESAT-6 (11). Animals vaccinated with BCG::RD1 in 
our study produced a robust T lymphocyte response (including TRM), 
with a significant proportion being specific to QQWNFAGIEAAASA, 
an MHC-II ESAT-6 tetramer. Tetramer+ cells only accounted for a 
small proportion of the overall increase in TRM numbers compared 
to BCG::pYUB- and BCG::RD1 ESAT-6 92–95–vaccinated groups. 
This suggests that memory lymphocytes were also generated against 
other ESAT-6 epitopes and epitopes from other ESX-1 proteins. Al-
though BCG::RD1 ESAT-6 92–95 expresses the same repertoire of 
Mtb-specific antigens as BCG::RD1, it did not show the same capacity 
to stimulate an enhanced T cell response, instead generating memory 
cell numbers comparable to BCG lacking ESX-1 altogether. These 
data suggest that functional ESAT-6 is not only required for the non-
cognate production of IFN- in vivo but is also required for the gen-
eration of a robust T lymphocyte (including TRM) response against 
ESX-1–secreted effectors. These results may guide the development of 
future rBCG strains that have the capacity to express Mtb antigens.
To account for vector-related effects on in vivo persistence and 
fitness, we used BCG::pYUB rather than “standard” BCG. Unexpect-
edly, this empty vector BCG strain induced the greatest amount of 
inflammation across all vaccine strategies that involved IT vaccina-
tion. Although our statistical analyses and VEIM use pYUB as the 
control to subtract vector effects, this highlights the importance of 
determining vector-related effects in early preclinical studies. How-
ever, a limitation of this study is that this strain may have caused 
immunopathology in excess of standard BCG, leading to an overes-
timation of the relative safety of the recombinant strains. None-
theless, the VEIM, which allows objective, simultaneous evaluation 
and ranking of various TB vaccination strategies used by other 
researchers in the field, is not affected by the use of BCG::pYUB. 
Furthermore, our findings that SC vaccination followed by an IT 
boost may be unsafe and that immunogenicity does not predict ef-
ficacy can be seen in all three BCG strains used and are, hence, not 
attributed to the use of BCG::pYUB.
The major benefit of using live vaccines is the stimulation of 
immune responses that most closely resemble those of natural in-
fection. However, live vaccines are often contraindicated in immuno-
compromised individuals (those who need protection the most). 
Ideally, live vaccines should stimulate a strong memory response and 
be readily cleared. BCG has been shown to persist for up to 16 months 
after vaccination, allowing for a period of ongoing antigenic stimu-
lation (37) but failing to confer a strong memory response in the 
pulmonary tissue. In our study, the numbers of recovered bacilli 
from the lungs of animals vaccinated with a single mucosal dose 
of either BCG::pYUB or BCG::RD1 ESAT-6 92–95 approximately 
halved within a 20-day period, suggesting that these strains are 
being cleared from the lung tissue. Bacilli recovered from the lungs 
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of BCG::RD1 IT–vaccinated animals, on the other hand, remained 
stable at 40 and 60 days after vaccination, supporting previous studies 
that this strain can persist in vivo (38). Although BCG::RD1 has been 
deemed too virulent for human use, our data suggest that a single 
mucosal or parenteral dose is safe (no loss in weight or health dete-
rioration following vaccination) in immunocompetent animals, de-
spite its persistence. Given that antigenic stimulation appears to be 
necessary for the retention of pulmonary TRM and only BCG::RD1 
was capable of eliciting a significant Mtb-specific T lymphocyte 
response in the pulmonary tissue, our study supports a model whereby 
the more “virulent” strains of attenuated mycobacteria need to be 
considered for use as vaccines against TB (38), if a benefit in protection 
can be demonstrated.
Currently, there is a lack of methods that permit simultaneous 
assessment of our experimental readouts of protection, immuno-
genicity, and safety mentioned above. Thus, we have developed VEIM 
to integrate routinely collected data from animal studies to rank and 
intuitively visualize vaccine strategies based on overall performance. 
Using this approach, two doses of BCG::RD1 administered paren-
terally rank as the most favorable vaccine strategy, characterized by 
being equally safe (if not safer) than control BCG::pYUB, immuno-
genic, and appearing more efficacious in protecting against disease. 
This supports a growing pool of evidence that live recombinant TB 
vaccines should express key Mtb virulence factors to enhance pro-
tection against pulmonary TB and that mucosal booster vaccination 
may cause adverse outcomes if administered at the peak of the 
primary immune response. Furthermore, our model demonstrates 
that despite selecting immunogenicity parameters based on current 
evidence, there does not appear to be a correlation between vaccine 
efficacy and immunogenicity. We find a small negative correlation 
(R2 = 0.15) driven by the low-immunogenic and high protection 
scores of BCG::RD1 (SC- or -SC) vaccination strategies. Together 
with previous reports (39), this finding highlights the limited under-
standing of the protective immune response against Mtb and cor-
relates of protection in infection models.
Our model, to the best of our knowledge, is the first that attempts 
to simultaneously compare different vaccine strategies to aid the 
stage-gating pipeline of TB vaccine development. However, our model 
makes a number of assumptions, built on a priori biological premise, 
such as that immunogenicity, safety, and efficacy are additive effects, 
that different cytokines should have equal effect and are reliant on 
baseline control experiments to score improvements. Figure S3 shows 
that VEIM can be used in a versatile manner to include/exclude or 
to change the weighting of particular parameters in the model. This 
will be important to reach a consensus in the research community 
on how safety, efficacy, and immunogenicity should be weighted. 
Our model also does not consider genetic diversity, which is known 
to affect vaccine immunogenicity and efficacy. Thus, it would be 
beneficial to include additional parameters that account for genetic 
diversity by including studies from, for example, genetically diverse 
collaborative cross mice (40). Furthermore, it may be beneficial to 
include a wide range of parameters such as tertiary lymphoid struc-
ture generation, local antibody levels, mucosal-associated invariant 
T cells, and readouts of trained immunity (41, 42) in future immuno-
genicity studies. Nonetheless, VEIM presents as an intuitive and 
readily extensible approach that allows for weighting of different 
parameters, numbers of replicates, and pairing of samples, and a 
simple assessment of multiple parameters that can be extended and 
applied more broadly to other vaccine/infection models. In particular, 
VEIM will be useful to dissect the relative importance of each in-
cluded parameter within a vaccination challenge experiment. For 
example, the current gold standard for assessing the efficacy of TB 
vaccines in mouse models is the bacterial burden after Mtb chal-
lenge. However, as shown here, most current TB vaccine candidates 
only lead to relatively small CFU changes within a relatively narrow 
range. The comprehensive approach of the VEIM allows for these 
minor differences to be incorporated into an additive score, which 
allows unbiased ranking of each vaccination strategy.
The adaptability of VEIM will allow for constructive discussion 
within the TB research community to further fine-tune VEIM based 
on current evidence. The integration and visualization of multiple 
parameters have reinforced the need to further investigate the relation-
ship between efficacy, immunogenicity, and safety. For example, what 
can we learn from the two relatively safe vaccination strategies of 
BCG::RD1(SC-) and BCG::pYUB (ITIT) that are highly protective, 
yet weakly immunogenic, or weakly protective, yet highly immuno-
genic to maximize overall vaccine performance?
In summary, our study provides evidence that parenteral admin-
istration of rBCG that expresses ESX-1 Mtb antigens enhances effi-
cacy in protecting against TB while also maintaining a safety level 
comparable to control BCG::pYUB. Our study highlights potential 
concerns regarding the safety of mucosally administering live BCG 
vaccines to individuals who have previously been vaccinated, which 
should be considered in clinical studies and trials. We also devel-
oped a model, VEIM, which allows for evaluation of novel TB vac-
cine strategies to identify those that are most likely to confer better 
protection against TB while also being safe for human use. Ap-
proaches such as VEIM, which aim to standardize and integrate the 
analysis of new TB vaccine strategies and aim to identify those most 
worthy of further investigation, are invaluable tools for benchmarking 
performance against the current standard BCG delivery.
MATERIALS AND METHODS
Animals
Female C57BL/6 mice aged 6 to 8 weeks were bred and maintained 
under stringent specific pathogen–free conditions in the biosafety 
levels 2 (BCG vaccination experiments) and 3 (Mtb challenge ex-
periments) animal facilities at the Australian Institute of Tropical 
Health and Medicine at James Cook University, Australia. Housing 
conditions included regulated ambient temperature (22°C) and 
lighting (12-hour light/12-hour dark cycle) with unlimited access to 
pelleted food and water in accordance with the Australian animal 
rights and regulations standards (equivalent to Institutional Animal 
Care and Use Committee guidelines). Animals were randomly allo-
cated to experimental groups.
Bacteria
BCG strains on the Pasteur background (provided by R. Brosch, 
Institut Pasteur, Paris) and Mtb H37Rv (sourced from the American 
Type Culture Collection) were cultured in Middlebrook 7H9 broth 
(BD Biosciences) supplemented with 0.2% glycerol, 0.05% Tween 80, 
10% ADC enrichment (BD Biosciences), and relevant antibiotics. 
Mid-logarithmic [OD600 (optical density at 600 nm), 0.6 to 0.8] 
cultures were harvested, washed in PBS, and stored at −80°C until 
required. Before vaccine administration, frozen stock vials of vac-
cines were thawed, and the bacteria were centrifuged for 12 min at 
3500 rpm. The resulting bacterial pellet was resuspended and diluted 
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in PBS to the appropriate density as required for vaccination or in-
fection (see below).
Vaccinations and infection
C57BL/6 mice were immunized with commonly used doses of BCG: 
2 × 105 CFU for IT vaccination or with 1 × 106 CFU for SC vaccina-
tion as shown in Fig.  1. Before IT immunizations, mice were 
anesthetized using a 1:16:160 xylazine-ketamine-PBS mixture ad-
ministered intraperitoneally. Once anesthetized, mice were suspended 
from their upper incisors, and 20 l of bacteria was inoculated into 
the oropharynx. The nostrils were occluded until the inoculum dis-
appeared from the oropharynx. SC injections were performed into 
the base of the tail. These procedures were performed on day 0 
(prime) and day 20 (boost) of the experimental timeline (Fig. 1). To 
determine protection conferred by vaccines, mice were challenged 
with an ultralow to low dose of Mtb H37Rv (5 to 80 CFU) via the 
aerosol route 90 days after vaccination using a Glas-Col inhalation 
exposure system. To determine the initial aerosol challenge dose, the 
lungs of five control mice were homogenized in 1 ml of PBS 0.05% 
(v/v) Tween 80, 24 hours after infection, and the entire volume of 
homogenized tissue was plated, incubated, and CFU was enumerated 
(refer to CFU enumeration below).
Animal weight and health score
Animals from each group were weighed weekly using an electronic 
scale and were assigned a daily clinical health score based on several 
parameters including general appearance, behavior, respiration char-
acteristics, and response to stimuli. Full health score criteria are 
provided in table S1. The lowest health score assigned during the 
course of the week was considered the overall health score for that 
7-day period.
Sample collection
Mice were euthanized using carbon dioxide asphyxiation or cervical 
dislocation. Blood for serum analysis was collected in serum separator 
tubes (BD Biosciences) from euthanized animals through cardiac 
puncture and allowed to sit for 4 hours. Coagulated blood was then 
centrifuged at 10,000 rpm for 6 min. Sera were stored at −20°C until 
analysis. To harvest the BALF, a small incision was made below the 
exposed larynx. Using an 18-gauge blunted needle, 1 ml of PBS was 
flushed into the lungs via the incision and aspirated. This was re-
peated three times to obtain a total of 3 ml of BALF per mouse. 
Organs were perfused with PBS through the left ventricle of the 
heart, and the lungs and spleen were harvested aseptically.
CFU enumeration
For enumeration of BCG colonies after vaccination, perfused post-
caval and inferior right lobes of the lung and spleen were homoge-
nized in 1 ml of PBS 0.05% (v/v) Tween 80, and 100 l was plated 
onto 10% OADC (BD Biosciences)–enriched Middlebrook 7H11 
(BD Biosciences or Cell Biosciences) agar plates containing hygro-
mycin B (50 g/ml; Sigma-Aldrich). All strains of rBCG used were 
resistant to hygromycin B. For Mtb CFU enumeration, perfused right 
lungs were homogenized in 1 ml of PBS 0.05% (v/v) Tween 80, and 
10-fold serial dilutions were performed (N, N−1, and N−2). Aliquots 
(100 l) were plated onto 10% OADC–enriched Middlebrook 7H11 
agar plates containing ampicillin (20 g/ml), cycloheximide (50 g/ml), 
and 2-thiophenecarboxylic acid hydride (2 g/ml) (Sigma-Aldrich). 
2- Thiophenecarboxylic acid inhibits the growth of BCG but not Mtb, 
thus allowing for enumeration of Mtb colonies only. In both in-
stances, plates were sealed with parafilm, wrapped in aluminum foil, 
and aerobically incubated for 4 weeks at 37°C. Colonies were then 
counted, and dilution factors were accounted for in calculating the 
total bacterial burden of organs.
Lung histology
Perfused left lung lobes from vaccinated unchallenged mice and 
unperfused left lung lobes from challenged mice were harvested and 
fixed in 10% neutral-buffered formalin for 24 hours and then stored 
in 80% ethanol at 4°C. Tissues were then processed and embedded 
in paraffin (HistoCore PEARL, Leica). Sections (4 m) were cut and 
transferred onto glass slides (Snowcoat Clipped Corner Slides, Leica). 
The tissues were then deparaffinized using xylene and ethanol washes, 
rehydrated, and stained with Harris H&E using a Leica ST4020 Small 
Linear Stainer. Images were captured on a dissecting microscope at 
×20 magnification. Histopathology/morphometric quantitation was 
performed using ImageJ (Fiji). The total area of lung tissue and areas of 
inflammatory change were calculated using the “Freehand selection” 
tool in ImageJ, which allows manual selection of areas of interest 
within an image.
Cell isolation and preparation for flow cytometry
Airway luminal cells were harvested from BALF. Perfused right su-
perior and middle lobes of the lungs were used for flow cytometry 
sample preparation. Lung-associated cells were prepared by cutting 
the tissue into small pieces using scissors. The diced tissue was incu-
bated for 30 min at 37°C in RPMI 1640 medium with 10% fetal bo-
vine serum (FBS), collagenase VIII (0.175 mg/ml), and collagenase 
D (0.075 mg/ml) (Sigma-Aldrich). Single-cell suspensions were 
prepared using mechanical dissociated through a 70-m nylon mesh. 
To eliminate red blood cells, cell suspensions were incubated with 
EDTA (Sigma-Aldrich) for 5 min at room temperature, washed with 
fluorescence- activated cell sorting (FACS) buffer solution (PBS 
with 2% FBS), and placed on ice until analysis.
Antibodies, tetramer, and flow cytometry
Identification of T cells was performed by using antibodies against 
CD3-A700 (clone 500 A2), NKp46-BV711 (clone 29A1.4), CD4-
BUV395 (clone GK1.5), CD8-BV510 (clone), CD44-BV421 (clone 
IM7), CD62L–phycoerythrin (PE)–Cy7 (clone MEL-14), CD103– 
allophycocyanin (APC) (clone M290), and CD69-PE-CF594 (clone 
H1.2F3), all purchased from BD Biosciences. The I-A(b) Mtb ESAT-6 
4–17 QQWNFAGIEAAASA tetramer (PE) was provided by the 
National Institutes of Health Tetramer Core Facility, USA. Fixable 
Viability Stain 780 (BD Biosciences) was used to exclude dead cells. 
Cells were incubated with viability stain for 10 min at room temperature 
and washed with FACS buffer solution. Samples were incubated with the 
tetramer (1:50 dilution) for 1 hour at room temperature and washed 
with FACS buffer solution. Cells were then incubated for 30 min 
with antibodies (1:200 dilution) on ice and washed with FACS buffer 
solution. Samples were resuspended in 150 l of blank calibration 
particles (BD Biosciences) diluted in FACS buffer solution (1:74). 
Samples were analyzed using a FortessaX20 analyzer (BD Biosciences). 
Cells were enumerated using calibration particles 6.0 to 0.4 m (BD 
Biosciences). CD3+NKp46− cells were considered T lymphocytes. 
Memory cells were phenotyped as follows: CD44hi CD62Lhi (TCM), 
CD44hiCD62LloCD103−CD69−/CD44hiCD62Llo CD103−CD69+/CD44hi 
CD62LloCD103+CD69− (TEM), and CD44hi CD62LloCD103+CD69+ (TRM). 
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The gating strategy for identifying tetramer+ CD4+ TRM is shown in 
fig. S2.
Serum multiplex analysis
Upon analysis, serum samples were thawed and prepared according 
to the Bio-Plex Pro Mouse Cytokine Standard 23-Plex Kit (Bio-Rad) 
specification. Serum samples were diluted in sample diluent (1:4), 
and beads and diluted samples were then incubated for 30 min at 
room temperature on a plate shaker at 850 rpm. The samples and 
beads were washed three times with wash buffer and then incubated 
with detection antibody as above. The samples and beads were re-
washed three times and were incubated with streptavidin as previ-
ously. Following another three washes, the samples and beads were 
resuspended in assay buffer. Measurements were conducted on a 
MAGPIX instrument (Luminex).
Serum immunoglobulin analysis
Upon analysis, serum samples were thawed and prepared according 
to the ProcartaPlex Mouse Antibody Isotyping Panel 2 7-Plex Kit. 
Serum samples were diluted in sample diluent (1:10,000), and bead 
and diluted samples were incubated for 60 min at room temperature 
on a plate shaker at 500 rpm. The samples and beads were washed. 
Detection antibody was added and allowed to incubate for 30 min 
at room temperature on a plate shaker at 500 rpm. The beads were 
rewashed and suspended in reading buffer. Measurements were con-
ducted on a MAGPIX instrument (Luminex).
Statistical analysis
Flow cytometry data were analyzed using FlowJo software version 
10 (Treestar, CA). Statistical analysis was performed, and graphs were 
generated using GraphPad Prism version 7.0 (GraphPad software). 
One-way analysis of variance (ANOVA) followed by the Dunnett’s 
multiple comparison test was used with all experimental groups being 
compared against unvaccinated (naïve) controls, following testing 
for normal distribution of data by D’Agostino-Pearson omnibus 
normality test. Such a statistical method was chosen so that the groups 
with the greatest differences were highlighted. Any bias from the use 
of this statistical method and the underrepresentation of statistical 
differences between groups were addressed through the VEIM 
model, which uses raw data. No data points were excluded. P values 
less than 0.05 were considered significant. Heat maps and graphs 
for cytokine/chemokine data were prepared on GraphPad Prism 
version 7.0.
Vaccine empirical integrated model
The VEIM was implemented in R version 3.5.1. Immunogenicityx 
(Eq. 1), safetyx (Eq. 2), and efficacyx (Eq. 3) were developed as three 
additive models, where x was one of the 24 vaccination strategies 
tested and u was the unvaccinated control. Overall scores were ranked, 
and the rank sum was used to rank each vaccine according to four 
different weighting scenarios for safety, efficacy, and immunogenicity 
(full results are shown in table S2 and fig. S3B). Calculations were 
done using the following equations
 immunogenicity x =  BALF x−u +  L x−u +  IGA x−u +
   1 ─3(IL  2 x−u + IL12p   70 x−u +  IFN x−u ) (1)
where BALFx−u, Lx−u, and IGAx−u represented the mean centered 
log10 z score difference of x versus u, and cytokines IL2x−u, IL12p70x−u, 
and IFNx−u equally weighted as one cytokine score as the addition of 
rescaled to detection limit z score differences.
 safety x =  W x−u +  C x−u +  L x−u +  S x−u +  H x−u + 
  1 ─3(IL1  b x−u + IL 6 x−u +  TNF x−u ) (2)
where Wx−u represents the mean centered z score difference of the 
maximum difference of mean weight at any time point observed 
(weeks 1 to 6); Cx−u is the difference of clinical scores; Lx−u, Sx−u, and 
Hx−u represent difference of negative rescaled to zero z scores for 
lung BCG, spleen BCG, and histopathology, respectively; and 
cytokines IL1bx−u, IL6x−u, and TNFx−u are equally weighted as one 
cytokine score as the addition of negative rescaled to detection limit 
z score differences
  efficacy x =  L x−u +  H x−u (3)
where Lx−u and Hx−u represent the negative z score difference of lung 
CFUs and histopathology, respectively.
Study approval
All animal experiments were conducted according to the Australian 
National Health and Medical Research Council (NHMRC) guidelines 
and in accordance with requirements by the animal ethics committee 
of James Cook University. Institutional ethics approval (A2346) 
for the studies was granted by the James Cook University Animal 
Ethics Review Committee.
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